All In Biotech

BLA 761065 · Theratechnologies

Trogarzo

Ibalizumab-Uiyk · Injection · CD4-directed Blocking Antibody; Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Mar 6, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

13

4 Phase 3, 1 recruiting

FAERS reports

540

220 serious, 38 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 7, 2026.

TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. TROGARZO, a CD4-directed post-attachment HIV-1 inhibitor, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

Mechanism: Ibalizumab-uiyk is an HIV-1 antiretroviral drug [see Microbiology ( 12.4 )] .

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 3, 2022 Supplement 13 · Efficacy OrphanLabel
  • Mar 6, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • TROGARZO · IBALIZUMAB-UIYK 150MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibalizumab" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue45
  • viral load increased45
  • drug ineffective44
  • rash43
  • hospitalisation36
  • fatigue30
  • off label use30
  • diarrhoea28
  • nausea26
  • death25
  • pruritus25
  • dizziness21

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20171
201845
201941
202073
202169
202286
202382
202466
202553
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trogarzo (Ibalizumab-Uiyk)

2024 spending

$12.4M

Beneficiaries

107

1,213 claims

Per beneficiary

$115,873

$1,096.33 per unit

View as table
YearSpending
2020$14,136,158
2021$12,698,850
2022$12,880,976
2023$14,106,188
2024$12,398,416

Part B: Trogarzo (Ibalizumab-Uiyk) · HCPCS J1746

2024 spending

$1.6M

Beneficiaries

19

235 claims

Per beneficiary

$82,264

2024 ASP limit $75.89 per unit

View as table
YearSpending
2020$1,608,887
2021$1,556,156
2022$1,681,553
2023$1,631,358
2024$1,563,019

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Theratechnologies

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.